论文部分内容阅读
目的:探究蚓激酶胶囊用于脑梗死中的疗效及安全性,供临床借鉴。方法:择我院2014年11月至2015年10月,接收的脑梗死患者,共82例。采用随机数字分表法,将82例患者均分成实验组与对照组。实验组行“常规+蚓激酶胶囊”治疗,对照组行常规治疗。观察并对比两组的疗效,记录并发症发病情况。结果:实验组总有效率97.56%,对照组80.49%。实验组的疗效,明显优于对照组。两组对比,差异具有统计学意义(P<0.05)。实验组仅1例患者出现上消化道出血并发症,所占百分比为2.44%,明显低于对照组14.63%。两组对比,差异具有统计学意义(P<0.05)。结论:利用蚓激酶胶囊,对脑梗死患者实施治疗,可提高用药的安全性,促进患者康复。
Objective: To investigate the efficacy and safety of lumbrokinase capsules in cerebral infarction for clinical reference. Methods: Select our hospital November 2014 to October 2015, received a total of 82 patients with cerebral infarction. Using random number table method, 82 patients were divided into experimental group and control group. The experimental group “conventional + lumbrokinase capsule ” treatment, the control group routine treatment. Observation and comparison of the two groups of curative effect, record the incidence of complications. Results: The total effective rate was 97.56% in the experimental group and 80.49% in the control group. The efficacy of the experimental group was significantly better than that of the control group. The difference between the two groups was statistically significant (P <0.05). Only one patient in the experimental group had upper gastrointestinal bleeding complications, accounting for 2.44%, significantly lower than the control group 14.63%. The difference between the two groups was statistically significant (P <0.05). Conclusion: The use of lumbrokinase capsules in the treatment of patients with cerebral infarction, can improve the safety of medication, and promote patient rehabilitation.